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Abstract: Ochratoxin A (OTA) is a nephrotoxin and carcinogen that is associated with 
Balkan endemic nephropathy and urinary tract tumors. OTA crosses the placenta and 
causes adducts in the liver and kidney DNA of newborns. Because the testis and kidney 
develop from the same embryonic tissue, we reasoned that OTA also may cause adducts 
transplacentally in the testis. We tested the hypothesis that acute exposure to OTA, via 
food and via exposure in utero, causes adducts in testicular DNA and that these lesions are 
identical to those that can be produced in the kidney and testis by the consumption of OTA. 
Adult mice received a single dose of OTA (from 0–1,056 µg/kg) by gavage. Pregnant mice 
received a single i.p. injection of OTA (2.5 mg/kg) at gestation day 17. DNA adducts were 
determined by 32P-postlabeling. Gavage-fed animals sacrificed after 48 hours accumulated 
OTA in kidney and testis and showed DNA adducts in kidney and testis. Some OTA 
metabolites isolated from the tissues were similar in both organs (kidney and testis). The 
litters of mice exposed prenatally to OTA showed no signs of overt toxicity. However, 
               
 
 
 
newborn and 1-month old males had DNA adducts in kidney and testis that were 
chromatographically similar to DNA adducts observed in the kidney and testis of  
gavage-fed adults. One adduct was identified previously as C8-dG-OTA adduct by LC 
MS/MS. No adducts were observed in males from dams not exposed to OTA. Our findings 
that in utero exposure to OTA causes adducts in the testicular DNA of male offspring 
support a possible role for OTA in testicular cancer. 
Keywords: ochratoxin; testicular cancer; DNA adduct; transplacental contamination; 
epidemiology 
 
1. Introduction  
Ochratoxin A (OTA) is a mycotoxin produced by species of Aspergillus and Penicillium that has 
long been studied as a nephrotoxin, immunotoxin, teratogen and carcinogen (for recent reviews  
see [1–3]). OTA contamination of grain is the cause of mycotoxic porcine nephropathy (a.k.a., “Danish 
nephropathy”), a renal disease of swine that is an important cause of economic losses in the pork 
industry [4,5] and may be responsible for some cases of nephropathy and cancer in humans [2]. 
Specifically, OTA is strongly implicated as the cause of Balkan endemic nephropathy (BEN), a fatal 
tubulointerstitial disease that is associated with renal atrophy [2,6,7] and that exhibits features similar 
to porcine nephropathy in Bulgaria [5,7]. Approximately 30% of patients dying with BEN have tumors 
of the urinary tract [6,8]. High amounts of OTA are found in human sera in regions where OTA 
contamination of food stuffs is high, particularly northern Europe (for reviews see [2,7]).  
Several areas of the Balkans that are known to have high levels of OTA-contamination of food have 
recently experienced a marked increase in the incidence of testicular cancer. For example, from 1960 
to 1985, the incidence of testicular cancer in Vas, Hungary, increased 5-fold, from 1.2 to 6.1/100,000 [9]. 
A similar increase was reported for Slovenia [9]. A possible etiologic role for OTA in testicular cancer 
in men was hypothesized in 2002 by Schwartz [10], who noted that the unusual geographic distribution 
of testis cancer, with especially high rates in Denmark, was correlated with the national per capita 
consumption of OTA-contaminated foods. Recent toxicologic data in rodents support the concept that 
dietary exposure to OTA can influence carcinogenesis in the testis. For example, Ueta et al., [11] 
administered 2 mg/kg OTA intraperitoneally to Pdn/Pdn mice on day 7.5 of gestation. They observed a 
significant depression of Dmrt-I gene expression in the male conceptuses on day 9 [11]. Dmrt-1 (also 
known as doublesex and mab-3 related transcription factor 1) is essential for the normal development 
of the mammalian testis [12]. More direct evidence of a carcinogenic role for OTA in the testis was 
provided by Mantle and Nolan [13]. These investigators administered 100 μg OTA as a daily dietary 
contaminant to 24 male Fischer rats for 35 weeks. Testis tumors developed in six of the rats (25%), an 
incidence rate equal to that of renal tumors in male Fischer rats chronically exposed to dietary OTA [14]. 
In adult rodents, OTA consumption causes adducts in liver, kidney and testicular DNA [15,16]. 
OTA also crosses the placenta and causes adducts in the liver and kidney DNA of newborns [17,18]. 
Because the testis and kidney develop from the same embryonic tissue, the mesonephros [19,20], we 
reasoned that OTA also may cause adducts transplacentally in the testis. We hypothesized that 
              
 
 
exposure to OTA during early life, either via consumption of foods that are contaminated with OTA or 
via exposure to OTA in utero, can cause lesions in testicular DNA. This research tests the hypothesis 
that in utero exposure to OTA causes adducts in testicular DNA and that these lesions are similar to 
those that can be produced in the kidney and testis by the consumption of OTA. 
In addition, we showed previously that OTA forms a benzoquinone electrophile following 
activation by cytochrome P450 enzymes and radical species following activation of enzymes with 
peroxidase activities. These electrophiles react preferentially with deoxy guanine to form 
benzethenoadduct and C8 dG-OTA. Analysis of OTA-mediated DNA adduct by 32P post labelling 
method correlates with OTA chemistry and adduct spots derived from quinone electrophiles which are 
generated following activation by cytochrome P 450, while a C-8 dG OTA adduct is formed following 
activation of OTA by peroxidises, mainly contained in kidney and testis (for a review see [21]). In this 
study we further characterized the OTA metabolites in tissues from adult animals exposed to OTA. 
2. Experimental Section  
2.1. Chemicals 
OTA (benzene free), 3′-dGMP, Proteinase K, RNase A, RNase T1 (boiled for 10 min at 100 °C to 
destroy DNases), and microccocal nuclease (dialyzed against deionized water) were purchased from 
Sigma-Aldrich (Saint-Quentin Fallavier, France); spleen phosphodiesterase (centrifuged before use) 
from Calbiochem (VWR, France); and nuclease P1 and T4 polynucleotide kinase from Roche 
(Meylan, France). [γ32P-ATP] (444 Tbq/mmol, 6000 Ci/mmol) was obtained from Amersham (Les 
Ullis, France); rotiphenol (pH 8) from Rothsichel (Lauterbourg, France); cellulose MN 301 from 
Macherey Nagel (Düren, Germany); polyethyleneimine (PEI) from Corcat (Virginia Chemicals, 
Portsmouth, VA); and Whatman No. 1 paper from VWR (France). Authentic 3’dGMP-OTA standard 
was prepared chemically prepared at Guelph University as described in detail [22]. All reagents, 
excluding solvents were of normal purity. Solvents were HPLC grade from ICS (Lapeyrouse-Fossat, 
France). Deionized water from a Milli-Q system (Millipore, France) was used for the preparation of all 
aqueous solutions for HPLC analysis. 
4-S-OH-OTA, 4-R-OHOTA, and 10 hydroxylated OTA (10-OH-OTA) were a gift from Dr 
Størmer. Quinone OTA (OTHQ) was prepared as described in Gillman et al., 1999 [23]. Glutathione 
(GSH) metabolites such OTHQ-GSH and OTA-GSH were formed in vitro by autooxidation as 
follows: 10 µM of either OTHQ or OTA dissolved in phosphate buffer (100 mM, pH 7.4) were 
incubated for 45 min at 37 °C in presence of 1 mM GSH. N-acetylcystein (NAC) metabolites such 
OTHQ-NAC and OTA-NAC were formed in vitro by autooxidation as follows: 10 µM of either 
OTHQ or OTA dissolved in phosphate buffer (100 mM, pH 7.4) were incubated for 45 min at 37 °C in 
presence of 1 mM NAC. 
2.2. Animals and Treatment 
2.2.1. Acute Gavage Feeding Studies 
Seven week-old male BALB/c mice, weighing 20g ± 2, were purchased from IFFA-CREDO, 
L’Arbresle, France and were housed in individual cages and kept in environmentally controlled 
              
 
 
conditions (ventilation, 22 °C, 12 hours dark/light cycles). After an acclimation period of one week,  
3 mice per group were given OTA dissolved in olive oil by a single intragastric intubation (oral 
gavage, 3.5; 7; 35; 70; 289; 578; 1056 µg/kg/b.w.). The control group of four mice received only olive 
oil. Mice were sacrificed 48 h after OTA administration. Testis and kidney were frozen immediately 
on dry ice and stored at −80°C pending analysis of OTA content, OTA metabolites content and  
DNA adducts.  
2.2.2. Subchronic Feeding Studies 
Seven week-old male BALB/c mice, weighing 20g ± 2, purchased from IFFA-CREDO, L’Arbresle, 
France were housed in individual cages and were kept under the same conditions as mice fed OTA by 
gavage. After an acclimation period of one week, 5 mice per group were given feed containing 
increasing amount of OTA (0.5, 1.4; 8; 20 µg/kg/b.w.) every day during 4 weeks. The feed (global 
rodent diets) was provided by Harlan Laboratory, Lyon, France. The feed was tested for the presence 
of mycotoxins after purification by partition for OTA, citrinin and aflatoxins and purification on IAC 
(Libios, France) for fumonisin B1 and zearalenone. The detection of the mycotoxins was performed by 
separation on HPLC with fluorimetric detection as described by Molinié et al., 2005 [24] and by 
Nguyen et al., 2007 [25]). None of these mycotoxins were detected. Feed was experimentally 
contaminated with OTA by mixing it with a solution of OTA to reach the desired concentrations. Five 
animals received feed without OTA as control. 
2.2.3. Transplacental Studies 
Six to 8 weeks old inbred Swiss (SWR/J) mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME, USA). We first performed studies to determine the potential toxicity of OTA delivered 
i.p. to Swiss mouse dams at day 17 of gestation. Dams were monitored for signs of overt toxicity. 
Potential toxicity to offspring was measured by determination of number of pups born, average litter 
weight, survival to weaning and weight at 1 month.  
Animals were housed in plastic cages with hardwood shaving bedding. They were maintained on a 
12 hours dark/light cycle and were allowed free access to food and water. After acclimation for two 
weeks, mice were mated by placing 2 to 3 females in a cage with one male. Pregnant mothers were 
treated on the 17th day of pregnancy (day one of pregnancy was the first day following overnight 
mating) by a high i.p. injection with either 2.5 mg/kg/b.w. OTA dissolved in olive oil or olive oil alone 
(control) at an equivalent volume.  
For adduct analysis, pups were sacrificed at birth, their gender was identified at necropsy, and 
kidneys and testes were removed from the males. Newborn testes and kidneys were frozen 
immediately following the same protocol as for the gavage-fed mice. Additionally, male mice from  
4 litters (two OTA-treated, two controls) were maintained for one month and then sacrificed. Kidney 
and testicular tissues were removed, frozen, and used for quantitation of DNA adducts. 
               
 
 
 
2.3. OTA and OTA Metabolites Determination in Tissues  
2.3.1. Analysis of OTA Content in Tissues of Adult Mice 
Tissue OTA content was extracted and measured as described by Petkova-Bocharova et al., 2003 
[26]. Briefly, 500 mg of tissue was homogenized with 10 mL of 0.1 M MgCl2/0.05 M HCl, pH 1.5 and 
extracted three times with chloroform. Combined chloroform extracts were extracted twice against 
sodium hydrogen carbonate, the aqueous phase acidified to pH 1.5, and further extracted with 
chloroform. Combined chloroform extracts were dried under vacuum, dissolved in methanol, filtered, 
dried under nitrogen and dissolved in 200 µL of methanol for HPLC analysis. OTA was analysed by 
reverse phase HPLC using a Nucleosil 100-3-C18 column, 15 cm under isocratic elution (Methanol, 
600 mL; acetonitrile, 600 mL; ultrapure water, 800 mL; sodium acetate, 3 H2O, 0.68 g; glacial acetic 
acid, 28 mL) run 30 minutes. Detection was performed with a programmable fluorimeter GTI 
spectrovision (excitation 340 nm, emission, 465 nm). HPLC grade solvent columns were supplied by 
ICS (Lapeyrouse-Fossat, France). The limit of detection (LOD) was 0.05 ng/g; the limit of 
quantification (LOQ) 0.2 ng/g. 
2.3.2. Analysis of OTA Metabolites in Tissues of Adult Mice 
The metabolites were separated on prontosil 250 mm × 4 mm, 3 µ using the following gradient: 
solvent A: MeOH/ACN/6.5 mM ammonium formate (200/200/600) adjusted to pH 3 with formic acid; 
solvent B: MeOH/ACN/6.5 mM ammonium formate (350/350/300) adjusted to pH 3 with formic acid. 
Program: T0 min 100% A; T10 min 100% A; T25 min 30% A; T30 min 30% A; T45 min 0% A;  
T55 min 0% A; T58 min as described in Faucet-Marquis et al., 2006 [27]. Detection was performed 
with a programmable fluorimeter GTI spectrovision (ex = 350 and em = 510 nm), allowing better 
detection of some OTA metabolites [28]. 
2.4. DNA Adduct Detection and Identification of C-C8dG OTA Adduct 
Kidney and testis DNA isolation and purification as well as the method used for 32P-postlabeling 
were performed as described by Faucet et al., [22] and in detail by Pfohl-Leszkowicz & Castegnaro 
[29]. In brief, the equivalent of 7 μg of DNA was dried in vacuo, dissolved in 10 μL of the mix 
containing 1 μL of micrococcal nuclease (2 mg/mL corresponding to 500 U), spleen phosphodiesterase 
(15 mU/μg DNA), 1 μL of sodium succinate (200 mM), and 1 μL of calcium chloride (100 mM, pH 6) 
and digested at 37 °C for 4 h. The digested DNA was then treated with 5 μL of the mix containing  
1.5 μL of nuclease P1 (4 mg/mL), 1.6 μL of ZnCl2 (1 mM), and 1.6 μL of sodium acetate (0.5 M,  
pH 5) at 37 °C for 45 min. The reaction was stopped by the addition of 3 μL of Tris base 500 mM. The 
DNA adducts were labeled as follows: to the nuclease P1 digest, 5 μL of the reaction mixture 
containing 2 μL of bicine buffer [bicine (800 μM), dithiothreitol (400 mM), MgCl2 (400 mM), and 
spermidine (400 mM) adjusted to pH 9.8 with NaOH], 10 U of polynucleotide kinase T4, and 100 μCi 
of [γ-32P]ATP (specific activity 6000 Ci/mmol) was added and the mixture incubated at 37 °C for  
45 min. Normal nucleotides, pyrophosphate, and excess ATP were removed by chromatography on 
PEI/cellulose TLC plates (D1) in 2.3 M NaH2PO4 buffer, pH 5.7, overnight. The original (2 cm) areas 
              
 
 
containing labeled adducted nucleotides were cut out and transferred to another PEI/cellulose TLC 
plate, which was run (D2) in 4.8 M lithium formate and 7.7 M urea, pH 3.5, for 3 h. A further (D3) 
migration was performed after turning the plate 90° anticlockwise in 0.6 M NaH2PO4 and 5.95 M 
urea, pH 6.4, for 3 h. Finally, the chromatogram was washed in the same direction in 1.7 M NaH2PO4, 
pH 6, for 2 h (D4). Adduct profiles were analyzed qualitatively and semi-quantitatively by 
autoradiography of the plates, carried out at −80 °C for 48 h in the presence of an intensifying screen 
using a radioanalytical system of image analysis (AMBIS, Lablogic).  
Identification of one DNA adduct was made by comigration with authentic standard. The standard 
OTA-3’P-dGMP adduct (C-C8) was dissolved in sterile deionised water. A dilution corresponding to 
143 fmol of adducts was 32P-postlabeled. OTA adduct in testis DNA was identified by either  
co-chromatography of DNA adducts from the testis (3.5 µg of digested DNA) and OTA standard or 
with DNA adducts from kidneys (3.5 µg of digested DNA in the conditions used for purified DNA). 
Isolation of this specific adduct was performed following the technique developed by Mantle et al., 
2010 [30]. In brief, the cellulose in the central area corresponding to spots of interest was scraped off. 
The cellulose was suspended in methanol, shaken and centrifuged; the solution and the extraction cycle 
was repeated. Residual cellulose was then similarly extracted with triethanolamine. Combined extracts 
were evaporated to dryness in vacuum. The residue was solved in methanol and put on PEI cellulose 
for additional D2, D3, D4. 
3. Results  
3.1. Acute and Subchronic Effect of OTA on Adult Male Mice 
Three animals per group received a single dose of OTA and were sacrificed 48 h after treatment. 
Three control animals received only vehicle. The control animals also were sacrificed 48 h later. For 
the subchronic study, five animals per group were fed OTA (in feed). DNA was extracted from kidney 
and testis. OTA and its derivatives were extracted and analyzed by HPLC. 
3.1.1. DNA Adduct Detection 
DNA adducts were analyzed in kidney and testes of male mice treated either acutely or 
subchronically by increasing amount of OTA using the postlabeling technique after nuclease P1 
enrichment. This technique allows detection of covalent DNA adducts only. No DNA adducts were 
observed either in kidney and testis of mice receiving only vehicle. Several individual DNA adducts 
are observed in kidney and testis after exposure over 7 µg/kg b.w. An example of DNA adduct patterns 
is shown in Figure 1.  
The numbers of individual adducts and the intensity of the DNA adducts increased with the 
exposure. A low exposure led mainly to the formation of the DNA adducts 1 and 2. High acute 
exposure induced at least 7 different DNA adducts (Figure 2 A). The DNA adducts formed in testis are 
similar to those formed in kidney (Figures 1C & D). DNA adduct 1 corresponding to C-C8dG OTA 
(see below 3.2.2 and Faucet et al., 2004 [22]; Mantle et al., 2010 [30]) is the main adduct in both 
organs. This adduct is also formed even after chronic exposure as low as 0.5 µg/kg b.w, and increased 
              
 
 
with dose (Figure 2B). Although adduct 6 is formed in both organs, it is formed to larger extent in 
kidney after acute exposure. After chronic exposure, adducts 2, 3 and 7 are also formed in testis. 
Figure 1. DNA adduct pattern in tissues of mice treated with Ochratoxin A. (A) kidney 
DNA from control mice; (B) testis DNA from control mice; (C) kidney DNA adduct from 
mice treated with 1056 mg/kg b.w.; (D) testis DNA adduct from mice treated with  
1,056 mg/kg b.w.; (E) Scheme of numbering of the individual DNA adducts. Exposure 
time of the film was 48 h. 
 
Figure 2. DNA adduct pattern in testis of male mice exposed to ochratoxin A. (A) acute 
exposure (gavage); (B) mice were fed 4 weeks with feed containing OTA. Doses are 
expressed as µg/kg b.w. The films were exposed for 24 h panel (A) and 48 h panel (B). 
 
The amounts of C-C8dG OTA observed in kidney and testis of mice exposed by gavage are given 
in Figure 3. The amount of C-C8 dG-OTA adduct (spot labeled number 1 in the scheme Figure 1) 
formed in kidney and testis are in the same range for dose treatment below 1056 µg/kg b.w. In the case 
of high exposure, the amount of C-C8dG OTA was 25% higher in testis than in kidney. 
              
 
 
Figure 3. Amount of C-C8dG OTA, expressed as relative adduct level, in organs of mice 
exposed to increasing amount of ochratoxin A (single dose). Amount in testis = hatched 
bar; amount in kidney = white bar. 
 
3.1.2. Amount of OTA in Kidney and Testis of Adult Mice 
Table 1 summarizes the OTA content in testis and kidney from BALB/c mice, administered 
increasing doses of OTA by a single gavage. The data show that the quantity of OTA stored in tissues 
increased with the dose administered, but the increase was not linear. The kidneys of male mice 
accumulated more OTA than did the testes at all doses. An increase in OTA administered over the low 
dose of 3.5 µg/kg b.w. by 300-fold led to an approximately 100-fold increase in OTA content in 
kidney. In the testis, OTA only accumulated when the dose was higher than 35 µg/kg b.w. 
(corresponding to 0.2 ppm in the feed). Following treatment of mice by a 15-fold higher amount of 
OTA (1,056 µg/kg b.w. vs. 70 µg/kg b.w.), the OTA in testis was 30-fold higher. 
Table 1. OTA content in kidney and testis of BALB/c treated with increasing 
concentrations of OTA by oral gavage 
OTA administered by gavage 
µg/kg b.w. 
OTA content in testis* 
ng/g 
OTA content in kidney* 
ng/g 
0 nd** nd 
3.5 nd 3.5 ± 1.4* 
7 nd 8.2 ± 0.7 
35 nd 110 ± 2.5 
70 1.6 ± 0.2 123 ± 2 
289 3 ± 0.1 110 ± 27 
578 9.6 ± 1.5 210 ± 30 
1056 50 ± 15 330 ± 60 
* average of three animals; ** not detectable (below limit of detection) 
              
 
3.1.3. Identification of OTA Metabolites in Tissues 
OTA and its metabolites were extracted from urine, liver, kidney and testis of mice fed increasing 
amount of OTA for 4 weeks. The metabolites were separated by gradient elution. An example of 
separation is given in Figure 4. Most of the OTA metabolites have been identified by  
LC MS/MS [27]). 
Figure 4. OTA metabolites detected in urine (A) and liver (B) of OTA treated males 
OTHQ (quinone OTA); GSH conjugated to glutathione; NAC conjugated to  
N-acetylcystein, DC OTHQ decarboxylated OTHQ; OP OA open ring OTA; OTB 
dechlorinated OTA; OTC ethylated OTA. 
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In male kidney and in testis, twelve metabolites were formed in both organs: OTβ; metabolite “2”; 
OTHQ-GSH; OTA-GSH; OTα; OTHQ-NAC; DC-OTHQ; 4R-OH-OTA; OTHQ; OTC. Two 
metabolites were observed in kidney but not in testis: 4S-OH-OTA and metabolite “9”. Some OTA 
metabolites were formed in liver but not in kidney and testis, such metabolites 3, 4, 6, 11 and OTB. 
The OTHQ metabolites (OTHQ; DC-OTHQ, OTHQ-NAC) are not detected in liver. 
3.2. Effect of Transplacental OTA Contamination on Male Mice Pup 
3.2.1. Transplacental Toxicity  
No overt toxicity of OTA was detected in either dams or litters. An average of 7–8 pups were 
delivered to both control and OTA-treated mothers, with an average birth weight of 1.5 g/pup and  
              
 
 
1.4 g/pup, respectively. Survival to weaning was also equivalent (50/57 in controls vs. 48/56 in  
OTA-treated) as was weight at 1 month of age (21.7 g/male and 18.4 g/female in controls vs.  
21.4 g/male and 18.2 g/female in OTA-treated) (Figure 5). 
Figure 5. Comparison of litter size, survival and weight of mice treated or not by OTA 
(CON = control animal; OTA = ochratoxin A treated animal). 
 
3.2.2. DNA Adduct Analysis in Kidney and Testis of Male Mice Pup 
DNA adducts were analyzed in kidney and testis from newborn male littermates exposed to OTA at 
17 days gestation and from 8 male mice aged 1 month. Three male mice were born from one mother 
and five from another. No adducts were detected in the testis and kidney of untreated mice. Several 
adducts were observed as well in kidney as in testis of pups born from OTA-treated mothers. A 
representative example of DNA adduct pattern in testis is shown in Figure 6. 
Figure 6. DNA adduct pattern of testis of one-month old mice. (A) litter from untreated 
mother mice; (B, C, D) litter from OTA-treated mother (arrow points C-C8dG OTA);  
(B & C) correspond to two animals from Mother Number 2; (D) corresponds to one animal 
from Mother Number 1. 
 
Mainly, three adducts were formed in kidney and testis of the male pups. These adducts correspond 
to adducts numbered “2”, “6”, “1” observed in adult mice (see Figure 1 for numbering). The intensity 
of the adducts differed according to the tissue and age of the animals. In newborn male mice adduct 
              
 
 
“6” is formed neither in kidney nor in testis. This suggest that adduct “6” likely results from OTA 
contamination via suckling, and explains why the DNA adduct amounts are higher in one month pups 
than in newborns. In order to confirm the structure of the adduct 1, comigration of testis DNA was 
performed with either kidney DNA or the C-C8 dGMP-OTA DNA standard. After D1 migration, the 
spot corresponding to C-C8dG OTA was cut out in each sample (Figure 7A). These spots were 
transferred onto a new plate and eluted in two dimensions. The main spot in kidney co-migrated with 
the main spot in testis. This spot co-migrated with C-C8 dGMP-OTA (Figure 7B). The structure of this 
adduct is given Figure 8. 
Figure 7. Comigration of mouse testis DNA with kidney DNA or C-C8 dG OTA standard (A) D1 
migration; The upper part is cut out and transferred onto new plates as described in Mantle  
et al., 2010 [30]; (B) C-C8dG OTA spot; Testis spot; comigration ½ C-C8dGOTA + ½ Testis; 
comigration ½ kidney + ½ testis. 
 
The mean C-C8dGMP-adduct level, measured on the organs in newborns, was 5.2 ± 0.1 and  
4.2 ± 0.2 nucleotides per 109 nucleotides in testis and kidney, respectively. The quantity of this latter 
adduct for each one-month old animal is shown in Table 2.  
Figure 8. Structure of C-C8 dG-OTA. 
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Table 2. Amount of C-C8dG OTA in kidney and in testis of one-month old mice 
contaminated with OTA via the transplacental route. 
 Animal 
Numbering 
C-C8dG OTA 
in Testis 
C-C8dG OTA in 
Kidney 
Mother 1 1 5.5 ± 0.3 4.8 ± 0.2 
2 5.7 ± 0.3 5.1 ± 0.3 
3 5.1 ± 0.3 4.7 ± 0.2 
Mother 2 4 7.3 ± 0.5 6.3 ± 0.2 
5 8.3 ± 0.5 6.5 ± 0.4 
6 7.7 ± 0.3 6.9 ± 0.5 
7 7 ± 0.6 6.6 ± 0.3 
8 7.8 ± 0.4 6.8 ± 0.5 
The amount of C-C8dG OTA was significantly higher in testis compared to kidney. Pups from the 
same mother have a similar amount of C-C8 dG OTA. 
4. Discussion 
Our results from gavage-feeding experiments are similar to those described previously [15,16]. 
Unlike Gharbi et al., [17], who administered 289 µg/kg b.w. OTA every 48 hrs for a period of 8 weeks 
(i.e., chronic administration), we showed that OTA induced adducts in testicular DNA after a single 
(acute) exposure using OTA doses that were 10-fold lower (<1 ppm in food). The number of 
individuals adducts increased with the dose. Daily intake of low amounts of OTA in feed induced the 
formation of the main adduct.  
To our knowledge, this is the first study to demonstrate that maternal exposure to OTA causes DNA 
adducts in the testis of newborn mice. These adducts are chromatographically similar to adducts in 
kidney and in testicular DNA that were produced by feeding OTA to adult mice by gavage. The main 
adduct observed in the testis comigrated with the C-C8dGMP OTA adduct which was also the main 
adduct in the kidney and has been recently identified by MS/MS (Mantle et al., 2010 [30]). This 
adduct is dechlorinated and thus could be formed only after OTA biotransformation [21,22,27,29,30]. 
The susceptibility of male rats to kidney cancer after OTA exposure is highly dependent on enzymes 
regulated by sexual hormones such CYP 2C [28] but also on enzymes involved in oxidative pathways 
[21] such cyclooxygenases [32–34] and glutathione conjugation [27,35]. Interestingly, Verma & 
Chakraborty [36] observed a decrease of catalase, SOD, glutathione peroxidase activities and of the 
amount of glutathione in testis of mice exposed to OTA. In testis and in kidney of mice fed OTA, we 
detected OTHQ formed via the peroxidase pathway [21]. In testis and kidney, several quinone 
metabolites were formed (OTHQ = ochratoxine hydroquinone; DC-OTHQ = decarboxylated OTHQ; 
OTHQ-GSH = conjugated to glutathione; OTHQ-NAC = conjugated to N-acetylcystein). These 
metabolites were not found in liver. This indicates that quinone formation arose in tissues having 
cylooxygenase, CYP 2C and glutathione conjugation pathways as it is the case mainly in kidney and 
testis. Interestingly, CYP 2C is induced by sex hormones [38] and is regulated by CYP 3A4 [38] which 
is abundantly expressed in the human liver, intestine and kidney. The CYP 3A5*1 allele was more 
prevalent in patients suffering from Balkan endemic nephropathy (BEN), for which OTA is a plausible 
              
 
 
etiologic agent, with a frequency of 9.4% versus 5.4% in controls, and was associated with a higher 
risk for BEN (Odds Ratio = 2.41) [39]. 
Adduct levels appeared to increase over time, as levels in month-old mice were greater than in 
newborns. This could be explained by the high affinity of OTA for proteins, accumulated in tissue of 
newborn and released for a long time after exposure. In addition, OTA is excreted in milk and thus 
exposure of the newborn to OTA continues after birth (for a review see [2]). 
The C-C8dGMP OTA adduct is the same adduct consistently observed in kidney tumors from 
patients with BEN in the Balkans and in other European countries [40–42]. In this regard, it is 
noteworthy that a recent epidemiologic study of BEN in the Vratza District, Bulgaria (where BEN was 
first characterized), found that cases of BEN in adults were associated with the presence of BEN in the 
mother, but not in the father [43]. These findings suggest that exposure to OTA in utero may play an 
etiologic role in BEN.  
Our finding that OTA caused DNA adducts in testes of newborns is consistent with the hypothesis 
of a possible role for exposure to OTA in testicular cancer [10]. Little is known about the etiology of 
testicular cancer, but its peculiar age-incidence curve, showing a peak in adolescence, and the 
identification of carcinoma in situ of the testis in pre-pubertal testes, suggests that the causes of 
testicular cancer occur in utero or peri-natally [44,45]. The only established cause of testicular cancer 
is cryptorchidism (failure of the testes to descend into the scrotum). However, it is widely believed that 
it is not cryptorchidism per se that causes testicular cancer, but rather, that cryptorchidism and 
testicular cancer share a common cause. A role for endocrine disruptors has long been suggested in 
testicular cancer, male infertility and in cryptorchidism (i.e., the “testicular dysgenesis syndrome”) but 
the identity of the agent(s) responsible for these epidemics is a mystery [46]. It is intriguing in this 
regard that OTA is known to cause inhibition of testosterone secretion [47], poor semen quality  
[48–50] and cryptorchidism. Thus, Wangikar et al., [51] found a significantly increased incidence of 
cryptorchid testes (2/12 OTA-treated pups vs. 0/43 controls) in Wistar rats given 0.75 mg OTA/kg on 
days 6–15 of gestation (P = 0.006). Similarly, Patil et al., [52] studied the effects of a single dose of 
OTAat 2.75 mg/kg body weight on maternal and fetal toxicity of pregnant Wistar rats. They observed 
a high incidence of gross abnormalities to fetuses from OTA exposure on gestation day (GD) 6 and 7 
(13 and 18%, respectively). Five instances of cryptorchid testes (of 92 foetuses examined) were 
observed on GD 6–10 and GD 13.  
The recent observation that Dmrt-1 gene expression is markedly reduced in conceptuses of male 
mice from dams treated with OTA is particularly noteworthy [11]. Although Dmrt-1 is essential for the 
embryonic development of the testis in humans, Dmrt-1 is involved in the postnatal development of 
the testis in rodents [53]. This may explain the development of testis cancer in older Fischer rats 
chronically exposed to OTA via the diet [13]. 
5. Conclusions 
We demonstrated that intrauterine exposure to OTA produces DNA adducts in the testes of 
newborn mice and that these adducts are similar to the DNA adducts that are observed in the kidney 
and testis of adult mice that are exposed to OTA via the diet. These data add additional support to the 
hypothesis that OTA may play a role in the etiology of testicular cancer [10].  
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